267 related articles for article (PubMed ID: 21191613)
41. Proposals for the management of gastrointestinal stromal tumours of the stomach.
Sujendran V; Fearnhead N; De Pennington N; Warren BF; Maynard ND
Surgeon; 2007 Jun; 5(3):149-53. PubMed ID: 17575668
[TBL] [Abstract][Full Text] [Related]
42. A large esophageal gastrointestinal stromal tumor that was successfully resected after neoadjuvant imatinib treatment: case report.
Yanagawa S; Tanabe K; Suzuki T; Tokumoto N; Arihiro K; Ohdan H
World J Surg Oncol; 2014 Feb; 12():47. PubMed ID: 24575748
[TBL] [Abstract][Full Text] [Related]
43. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
[TBL] [Abstract][Full Text] [Related]
44. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
[TBL] [Abstract][Full Text] [Related]
45. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
Yamaguchi M; Matsumoto T; Tate G; Higuchi T
J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
[No Abstract] [Full Text] [Related]
46. Could imatinib replace surgery in esophageal gastrointestinal stromal tumor.
Al-Salam S; El-Teraifi HA; Taha MS
Saudi Med J; 2006 Aug; 27(8):1236-9. PubMed ID: 16883460
[TBL] [Abstract][Full Text] [Related]
47. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
Wu PC; Langerman A; Ryan CW; Hart J; Swiger S; Posner MC
Surgery; 2003 Oct; 134(4):656-65; discussion 665-6. PubMed ID: 14605627
[TBL] [Abstract][Full Text] [Related]
48. Gastrointestinal stromal tumour treated with neoadjuvant imatinib.
Loughrey MB; Mitchell C; Mann GB; Michael M; Waring PM
J Clin Pathol; 2005 Jul; 58(7):779-81. PubMed ID: 15976351
[TBL] [Abstract][Full Text] [Related]
49. Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate.
Colović R; Micev M; Matić S; Colović N; Grubor N; Atkinson HD
Vojnosanit Pregl; 2013 Feb; 70(2):225-8. PubMed ID: 23607193
[TBL] [Abstract][Full Text] [Related]
50. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
Rink L; Skorobogatko Y; Kossenkov AV; Belinsky MG; Pajak T; Heinrich MC; Blanke CD; von Mehren M; Ochs MF; Eisenberg B; Godwin AK
Mol Cancer Ther; 2009 Aug; 8(8):2172-82. PubMed ID: 19671739
[TBL] [Abstract][Full Text] [Related]
51. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
52. A metastatic case of gastrointestinal stromal tumor (GIST) treated with imatinib mesylate (Glivec(®)) in Mali.
Diallo DA; Ly M; Diallo G; Dembélé AK; Touré M; Touré BA; Koné A; Sidibé S; Dembelé M; Traore BC
Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):675-7. PubMed ID: 21641899
[TBL] [Abstract][Full Text] [Related]
53. Modern treatment of gastric gastrointestinal stromal tumors.
Roggin KK; Posner MC
World J Gastroenterol; 2012 Dec; 18(46):6720-8. PubMed ID: 23239909
[TBL] [Abstract][Full Text] [Related]
54. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
[TBL] [Abstract][Full Text] [Related]
55. Clinical, radiological, and pathological findings in four children with gastrointestinal stromal tumors of the stomach.
Sauseng W; Benesch M; Lackner H; Urban C; Kronberger M; Gadner H; Höllwarth M; Spuller E; Aschauer M; Horcher E
Pediatr Hematol Oncol; 2007; 24(3):209-19. PubMed ID: 17454792
[TBL] [Abstract][Full Text] [Related]
56. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
57. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
58. Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor.
Hou YY; Zhou Y; Lu SH; Qi WD; Xu C; Hou J; Tan YS
World J Gastroenterol; 2009 Apr; 15(15):1910-3. PubMed ID: 19370794
[TBL] [Abstract][Full Text] [Related]
59. Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall.
Lam MM; Corless CL; Goldblum JR; Heinrich MC; Downs-Kelly E; Rubin BP
Int J Gynecol Pathol; 2006 Jul; 25(3):288-92. PubMed ID: 16810068
[TBL] [Abstract][Full Text] [Related]
60. Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST.
de Azevedo CR; Paiva TF; Rossi BM; Guimarães GC; de Souza Begnami MD; Oliveira TB; Barros E Silva MJ; Fanelli MF; de Mello CA
Int J Clin Oncol; 2011 Jun; 16(3):279-83. PubMed ID: 20922448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
